Role of innate T cells in anti-bacterial immunity

Yifang Gao* and Anthony P. Williams

Innate T cells are a heterogeneous group of αβ and γδ T cells that respond rapidly (<2h) upon activation. These innate T cells also share a non MHC class I or II restriction requirement for antigen recognition. Three major populations within the innate T cell group are recognized, namely, invariant NKT cells, mucosal associated invariant T cells, and gamma delta T cells. These cells recognize foreign/self-lipid presented by non-classical MHC molecules, such as CD1d, MR1, and CD1a. They are activated during the early stages of bacterial infection and act as a bridge between the innate and adaptive immune systems. In this review, we focus on the functional properties of these three innate T cell populations and how they are purposed for antimicrobial defense. Furthermore, we address the mechanisms through which their effector functions are targeted for bacterial control and compare this in human and murine systems. Lastly, we speculate on future roles of these cell types in therapeutic settings such as vaccination.

Keywords: iNKT cells, MAIT cells, gamma delta T cells, innate T cells, bacterial infections

A successful immune response to foreign pathogen requires a rapid activation of innate immunity, which directs the subsequent development of a productive adaptive immune response. Innate T cells represent a group of T lymphocytes that are able to act during the lag time while effective adaptive immune responses develop (1). Similar to conventional T cells, innate T cells undergo T cell receptor (TCR) rearrangement and thymic selection. Unlike their conventional counterparts, innate T cells rapidly recognize foreign pathogen signals and manifest immediate effector functions after activation. This allows innate T cells to perform effector immune responses much earlier than conventional T cells, and act as an additional “bridge” between innate and adaptive immune responses (2).

Classically, T cells are subdivided into two major populations based upon their TCR expression, namely alpha beta (αβ) T cells and gamma delta (γδ) T cells. Conventional αβ T cells recognize a broad range of peptide antigens typically presented by Major Histocompatibility Complex (MHC I and II) complexes, enabled through their highly diverse TCR arrangement. In contrast, the αβ innate T cells that have been identified display a restricted T cell repertoire characterized by the expression of an invariant or semi-invariant TCR α chain. In humans, two well-defined αβ innate T cell populations have been identified in recent years, namely, mucosal-associated invariant T (MAIT) cells and invariant natural killer T (iNKT) cells. These two T cell populations together with γδ T cells form the three major types of innate T cell (1). All three innate T cell populations express a C-type lectin molecule CD161. CD161 was initially identified on CD4, CD8, and γδ subsets in the 1990s (3, 4). CD161 is variably expressed across human T cells, and three populations can be identified, expressing negative, intermediate, and high levels of CD161 (2). The expression of CD161 in human T cells populations is summarized in Figure 1. The level of CD161 expression is distinctive between conventional T cells and innate T cells, with MAIT cells displaying the highest levels (5).
While innate T cells are distinctive as a subpopulation of T cells, they have other distinct features, which do not overlap. They share the absence of MHC I/II peptide restriction but differ in their respective antigen presentation modalities. iNKT and MAIT cells respond to the MHC-like molecules, CD1d and MR1, respectively, while CD1c can present antigens to γδ T cells. The nature of the antigens recognized by innate T cells is also diverse and broadly non-overlapping involving metabolites, bacterial products, and lipids. iNKT cells have been principally shown to respond to glycolipids, γδ T cells are potently activated by (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMBPP), and MAIT cells can be activated by riboflavin metabolites – reduced 6-hydroxy methyl-8-β-ribitylumazine (rRL-6-CH₂OH), as well as folic acid metabolite, 6-formyl pterin (6FP). Finally, the sites of development, residence, and frequency within the T cell pool are distinctive and summarized in Table 1.

iNKT Cells

Invariant NKT cells are one of the most well-studied innate T cell populations (6–8). These cells are defined by their semi variant TCR, CD1d antigen restriction, and glycolipid recognition. Numerous studies have been undertaken with these cells following the discovery of their specific ligand, alpha-galactosylceramide, in 1997 (7, 9–11). Over the subsequent years, a range of endogenous and exogenous lipid antigens has been identified, which may change the effector responses of this innate T cell population (12–16). This cell population is also notable for its expression of previously considered NK cell specific markers such as CD161, which has subsequently been recognized on other innate T cell populations (17).

Invariant NKT cells develop in the thymus and are present at a very low number in most tissues. They are selected by CD1d, which is expressed on double-positive (CD4, CD8) thymocytes, through the recognition of endogenous lipids. In the thymus, iNKT cells acquire a memory/effector phenotype prior to exiting to the circulation. Recent studies have suggested that post-thymic education is required for iNKT cells to become fully mature and achieve functional competency (18, 19). In human peripheral blood, approximately 0.01–1% of the T lymphocytes are iNKT cells, characterized by their hallmark TCR-invariant chain Vα24-Jα18 and variant Vβ11; and Vα14-Jα18 in mice with a limited number of β chains, including Vβ8.2, Vβ7, and Vβ2 (20). Despite their presence in relatively low numbers in humans, iNKT cells can be very effective in early host defense mechanisms and are involved in a variety of disease settings (6, 21–23). A key feature of iNKT cells is their rapid release of a wide array of cytokines and chemokine following ligand activation (17). This plays an
important role in their early effector and regulatory properties. Our understanding of the importance of iNKT cells is largely based on disease studies undertaken in iNKT deficient mice (24). Previous studies have shown that iNKT cells play an important role in the detection of various pathogens, including *Pseudomonas aeruginosa*, *Streptococcus pneumoniae*, *Salmonella typhimurium*, *Mycobacterium tuberculosis*, *Listeria monocytogenes*, and *Borrelia burgdorferi* (1, 25, 26). In addition to bacterial infections, iNKT cells have also been found to play an important role in viral infections, including influenza, cytomegalovirus, and coxsackie B3 viral diseases (25, 27). Finally, they also play an important role in tumor immunity (28) and autoimmune disease (22). In human studies, a link between defects in iNKT cells may lead to susceptibility to certain infectious diseases, such as tuberculosis (29, 30), EBV (31–33), allergy (34), atherosclerosis (35), and immunodeficiency. (10, 36–38).

**Role During Bacterial Infections**

The presence of functional iNKT cells during bacterial sepsis has been shown in a number of different murine settings. In *S. pneumoniae* infection, a much higher level of bacteria were identified in the Jα18 knockout mice compared to the iNKT competent wild type mice, resulting in significant survival rate differences between the two strains (39). In the iNKT knockout mice, a defect was found in neutrophil recruitment to the lung together with a reduced production of neutrophil chemoattractants, including TNF-alpha and MIP-2. A reconstitution of iNKT cells from wild-type mice to iNKT deficient mice was able to restore the production of TNF-alpha and MIP-2, leading to improved neutrophil and bacterial clearance (40). In a further bacterial infection caused by *Chlamydia pneumoniae*, accumulations of iNKT cells within the lung were visible within hours of acute infection, demonstrating IFN-gamma production at the site of infection (41). An extension of conventional bacterial challenge studies have recently been undertaken by Wong et al., which suggested that iNKT cells might play a role in control of bacterial infections associated with stroke. Compared to their WT little mate, iNKT deficient mice were found to be more susceptible to bacterial infection post transient midcerebral artery occlusion. This was related to the ability of iNKT cells to act as a suppressor for neurotransmitter release post-stroke, which is lost in iNKT deficient mice, making them more susceptible to the bacterial infection (42). In humans, several studies have established the link between iNKT cells and *M. tuberculosis* infection with both the function and number of iNKT cells reduced in these patients (43). Two distinct pathways have been proposed for iNKT cell activation during infection. They can either be directly activated through TCR-CD1d-glycolipid recognition or indirectly through their response to innate cytokines that are released from other innate cells.

**Indirect Activation of iNKT Cells by Gram-negative Bacteria**

Early secretion of IFN-gamma can be induced by iNKT cells following an encounter with both Gram-negative and Gram-positive bacteria. Innate receptors that recognize bacterial signals have a crucial role in triggering the antigen presenting cells, which subsequently direct the activation of iNKT cells (9, 44–49). The activated antigen presenting cells stimulate the iNKT cells by signaling through toll like receptors (i.e., TLR4, TLR7, and TLR9) leading to the production of IL-12, also other inflammatory cytokines. Studies by De Libero and Paget have suggested that TLR signaling through APCs are not only important for cytokine production but also the accumulation of self-lipid antigen for CD1d presentation (47, 50). A study by Darmoise et al. showed that the TLRs signaling triggered the accumulation of self-lipid including iGb3 in the lysosome, leading to an enhanced iNKT cell activation (51).

**Direct Activation of iNKT Cells by Gram-negative Bacteria**

Another mechanism that allows iNKT cells to respond to bacterial infection occurs through the direct recognition of the glycosphingolipid in the cell wall of Gram-negative bacteria. One such example is *Sphingomonas/Novosphingobium spp.*, where the glycosphingolipids present in the bacteria cell wall are alphagalacturonanlyceramides and alphagalacuronylceramides (52). These glycosphingolipids contain one sugar ring and have been shown to activate iNKT cells in vitro, while multi-sugar ring glycosphingolipids have not been able to activate iNKT cells in co-culture. Murine studies suggested that CD1dKO mice were able to clear infections with *Sphingomonas/Novosphingobium* as well as some other LPS-negative bacteria, but at a much slower rate compared to the wild type mice (45, 53, 54). This would suggest the iNKT cells are one of the major innate cell types involved in bacterial clearance and playing a major role in the early response.

**γδ T Cells**

γδ T cells are another group of innate T cells that have been found to play an important role during bacterial infections. Unlike conventional αβ T cells, γδ T cells do not usually express a CD4 or CD8 lineage marker and they do not require conventional antigen presentation via MHC class molecules (55). Different subtypes of γδ T cells have been described often identified by the different arrangement of their TCRs in early development. The differences in TCR arrangement directly influence their eventual principle
tissue of residence. In human, the majority of the \( \gamma \delta \) T cells present in the peripheral blood express the TCR V\( \gamma \)9V\( \delta \)2, whereas V\( \delta \)1 and V\( \delta \)3 TCR are primarily expressed at the mucosal surfaces. In mice, V\( \gamma \)1 and V\( \gamma \)4 are present in the lymphoid tissues; V\( \gamma \)5 is found to be present in the skin; V\( \gamma \)6 in the reproductive tract; and V\( \gamma \)1, V\( \gamma \)4, and V\( \gamma \)6 present in the lung (56). A number of mechanisms have been described linking \( \gamma \delta \) cells and bacterial infections. Similar to iNKT cells, \( \gamma \delta \) T cells are able to sense danger signals in both a TCR dependent and TCR independent way. \( \gamma \delta \) T cells can be activated by Class I like molecules such as T10/T22 (in mice) and members of CD1 family; they can also be activated by MHC-unrelated molecules such as viral glycoproteins and F1-ATPase complex in human (57–59). In addition to TCR recognition, \( \gamma \delta \) T cells also express pattern recognition receptor and receptor typically associated with NK cells.

\( \gamma \delta \) T cells may expand in the patient’s peripheral blood during bacterial infections with studies identifying up to 12% in listeriosis, 14% in tuberculosis, and 29% in brucellosis (60). Human \( \gamma \delta \) T cells respond to bacterial infections by recognizing (E)-4-hydroxy-3-methyl-but-2enyl pyrophosphate (HMBPP) derived from various bacteria. \( \gamma \delta \) T cells were shown to be particularly important in response to intracellular bacterial pathogens including M. tuberculosis and Legionella micdadei. In the case of L. micdadei, V\( \gamma \)9V\( \delta \)2 T cells were found to be depleted from the circulation upon bacterial infection, followed by a sharp increase, then a slow decline over a 6-month-period (61). This dynamic change may indicate V\( \gamma \)9V\( \delta \)2 might be important in contributing to the pathophysiological changes of Pontiac fever-like disease. A similar kinetic pattern is seen with M. tuberculosis infection, following the V\( \gamma \)9V\( \delta \)2 T cell response to the metabolite IPP (62).

Early studies found that V\( \gamma \)9V\( \delta \)2 T cells were the most important group that led to the eradication of bacteria (63, 64). Seminal studies identified the antigens involved in the recognition were intermediates in isoprenoid biosynthesis, namely (E)-4-hydroxy-3-methyl-but-2enyl pyrophosphate (HMBPP) (65). The level of HMBPP directly influences the magnitude of V\( \gamma \)9V\( \delta \)2 T cell activation and proliferation (66). Recently, a major breakthrough in discovering the mechanisms for activating the V\( \gamma \)9V\( \delta \)2 T cells was made by Bonneville and Scotet's group. They identified that a member of butyrophilin molecule family CD277 played a crucial role during \( \gamma \delta \) T cells activation (67–71).

\( \gamma \delta \) T cells have also been found to be able to promote self-activation through cell to cell interaction (72). However, it was demonstrated that the self-activation mechanism is not as effective as formal presentation through antigen presenting cells (73–75). One important aspect of \( \gamma \delta \) T cells is that they can trigger the maturation of dendritic cells. Devilder et al. showed that V\( \gamma \)9V\( \delta \)2 T cells can stimulate the maturation signal on mycobacterial infected DCs, through a Fas–Fas ligand interaction (76) and/or TCR-CD1 contact (77). Other than dendritic cells, \( \gamma \delta \) T cells have also been found to be important in macrophage recruitment. During infection with listeriosis, \( \gamma \delta \) T cells were found to be a key player in controlling the production of key macrophage chemo attractants (78). Skeen et al. also showed that macrophages failed to undergo maturation in the absence of \( \gamma \delta \) T cells (79). Direct engagement of \( \gamma \delta \) T cells may facilitate pathogen clearance through their production of bacteriostatic and lytic molecules, such as granulysin and defensins. During Staphylococcus aureus respiratory infection, \( \gamma \delta \) T cells sense the dysregulation of the mevalonate pathway within the infected cells. This leads to the activation and expansion of \( \gamma \delta \) T cells, in particular, V\( \gamma \)9V\( \delta \)2 T cells. The active \( \gamma \delta \) T cells then produce cytokines such as IL-17, which leads to airway protection. \( \gamma \delta \) T cells also play a role during M. tuberculosis infection, producing a variety of cytokines including IFN-\( \gamma \), TNF-\( \alpha \), and IL-17. IFN-\( \gamma \) and TNF-\( \alpha \) play are essential in host protection against M. tuberculosis enabling granuloma formation and disease containment.

**MAIT Cells**

Mucosal-associated invariant T cells are the newest members of the innate T cell family. They were first described by Tilloy et al. (80) and represent the most abundant innate T cells in humans. They express a canonical Va7.2-Ja33 chain in humans and the orthologous Va19-Ja33 in mice. The development of MAIT cells is parallel to the development of iNKT cells and both express the transcription factor ZBTB16 (81). In adults, they display an effector phenotype, whereas MAIT cells possess a naïve phenotype in cord blood. In both cord and adult blood, MAIT cells express CD161, 1L-18Ra, CCR6, and about 50% of the MAIT cells express the T cells co-receptor CD8 (82–84). Recent studies also show that MAIT cells express the ABC binding cassette (ABC) B1 drug resistance transporter (85, 86). MAIT cells have a further unique antigen recognition system recognizing a MHC Class I related molecule (MR1), which is able to present bacterial derived ligand. Study by Kjern-Nielsen et al. showed that 6-formyl pterin (6-FP), a metabolite on the folic acid pathway, could stabilize the MR1 molecule but failed to activate the cells. Full activation of primary MAIT cells was achieved with ligand reduced 6-hydroxymethyl-8-d-ribitylumazine (rRL-6-CH2OH), a riboflavin metabolite. Related products 7-hydroxy-6-methyl-8-d-ribitylumazine (RL-6-Me-7-OH) and 6,7-dimethyl-8-d-ribitylumazine (RL-6,7-diMe) have also shown similar agonistic activity for MAIT cells, leading to the rapid production of cytokines (87). In recent years, studies on MAIT cells have associated their number and function with diverse of disease settings, including bacterial infections and autoimmune disorder.

The first hint that MAIT cells have anti-bacterial activities was described in 2010, where studies by Gold et al. and Le Bourhis et al. showed that MAIT cells could recognize a range of bacteria species through MR1 (88, 89). In the study by Gold et al., MAIT cells could respond to M. tuberculosis even in unexposed individuals. They further showed that MAIT cells responded to Salmonella enterica, Eschecchia coli, and S. aureus infected APC (90). Le Bourhis et al. showed that MAIT cells could MAIT cells are able to respond to a wide array of bacteria including Gram-positive Bacteria S. aureus, Staphylococcus epidermidis, Lactobacillus acidophilus, and Gram-negative Bacteria E.coli, Klebsiella pneumonia, Pseudomonas aeruginosa, and Mycobacterium abscessus. Importantly, some bacterial species were shown not to activate MAIT cells, namely Enterococcus faecalis and Streptococcus pyogenes, suggesting a novel specificity. The importance of their role in bacterial defense was suggested by a study by Georgel et al. demonstrating that during the Klebsiella pneumonia infection, MR1 deficient mice succumbed to disseminated infection whereas the WT mice.
achieved full bacteria clearance within 2 days (91). Similarly, in the Va19 transgenic mice, enhanced control of the E.coli and M. abscessus infection were observed. Further studies performed by Chua et al. and Meierovics et al. also showed that MAIT cells were needed in the early control of Mycobacterium bovis, BCG, and Francisella tularensis infection (92, 93). In humans, how MAIT cells play a role in infectious disease is less well understood. A number of studies have associated the frequency of MAIT cells in different infectious diseases (94). MAIT cell numbers were found to be lower in peripheral blood of patients with M. tuberculosis infection (95). Also, in a study of critically ill septic and non-septic patients, the patients with severe bacterial infections, but not viral infections, had a much lower MAIT count compared to healthy controls (96).

One of the most well-studied examples of MAIT cells in bacterial infection is during Salmonella infection (97, 98). Upon activation, MAIT cells produce IFN-gamma, TNF α, and IL-17. These cytokines have been shown to be critical in controlling Salmonella infections, with IL-17 preventing the dissemination of infection (99). MAIT cells may also play a role during Salmonella infection through their early cytotoxic activity (100), although further studies are needed as MAIT cells were not able to directly kill Salmonella infected cell lines (94, 101).

Over the last 5–10 years, there has been advancement in the understanding and description of unconventional T cells. These studies demonstrate that unconventional T cells do indeed play an important role during bacteria infection and contribute the ability of host organism to clear and control certain bacterial infections (Figure 2). These cells are able to efficiently traffic to the sites of inflammation, and initiate rapid responses by means of cytokine production and cytotoxic activities. Further studies will elucidate the molecular details of this cellular control suggesting novel approaches to how we may harness these cells through therapeutic vaccination and pharmaceutical manipulations.

Acknowledgments

YG and APW were supported by Cancer Research UK and the Experimental Cancer Medicine Centre, Southampton.
References

1. Ivanov S, Paget C, Trottein F. Role of non-conventional T lymphocytes in respiratory infections: the case of the pneumococcus. *PLoS Pathog* (2014) 10(10):e1004300. doi:10.1371/journal.ppat.1004300

2. Ferguson JR, Smith KE, Fleming VM, Rajoriya N, Newell EW, Simmons R, et al. CD161 defines a transcriptional and functional phenotype across distinct human T cell lineages. *Cell Rep* (2014) 9(3):1075–88. doi:10.1016/j.celrep.2014.09.045

3. Lanier LL, Chang C, Phillips JH. Human NKR-P1A. A disulfide-linked homodimer of the C-type lectin superfamily expressed by a subset of NK and T lymphocytes. *J Immunol* (1994) 153(6):2417–28.

4. Battistini L, Borsellino G, Sawicki G, Poccia F, Salvetti M, Ristori G, et al. Phenotypic and cytokine analysis of human peripheral blood gamma delta T cells expressing NK cell receptors. *J Immunol* (1997) 159(8):3723–30.

5. Martin E, Treiner E, Duban L, Gueri L, Laude H, Toly C, et al. Stepwise development of MAIT cells in mouse and human. *PLoS Pathog* 2009 7(3):e54. doi:10.1371/journal.pbio.1000054

6. Benedac A, Savage PB, Teyton L. The biology of NKT cells. *Annu Rev Immunol* (2007) 25:297–336. doi:10.1146/annurev.immunol.25.022106.141711

7. Cohen NR, Garg S, Brenner MB. Antigen presentation by CD1 lipid, T cells, and NKT cells in microbial immunity. *Adv Immunol* (2009) 102:1–94. doi:10.1016/S0065-2776(09)92101-2

8. Kinjo Y, Kitano N, Kronenberg M. The role of invariant natural killer T cells in microbial immunity. *J Infect Chemother* (2013) 19(4):560–70. doi:10.1007/s10156-013-0638-1

9. Brigl M, Tatituri RV, Watts GF, Bhowruth V, Leadbetter EA, Barton N, et al. Phenotypic and cytokine analysis of human peripheral blood gamma delta T cells in simian immunodeficiency virus-infected macaques. *PLoS Pathog* (2008) 4(12):e1000239. doi:10.1371/journal.ppat.1000239

10. Brennan PJ, Brigl M, Brenner MB. Invariant natural killer T cells: an innate activation scheme linked to diverse effector functions. *Nat Rev Immunol* (2013) 13(2):101–17. doi:10.1038/nri3569

11. Paget C, Ivanov S, Fontaine J, Blanc F, Pichavant M, Rennesson J, et al. Potential role of invariant NKT cells in the control of pulmonary inflammation and CD8+ T cell response during acute influenza A virus H3N2 pneumonia. *J Immunol* (2011) 186(10):5390–602. doi:10.4049/jimmunol.1002348

12. van der Sluijs KF, van der Poll T, Lutter R, Juffermans NP, Schultz MJ. Bench-to-bedside review: bacterial pneumonia with influenza – pathogenesis and clinical implications. *Crit Care* (2010) 14(2):219. doi:10.1186/cc8893

13. Tessmer MS, Fatima A, Paget C, Trottein F, Brossay L. NKT cell immune responses to viral infection. *Expert Opin Ther Targets* (2009) 13(2):153–62. doi:10.1517/14712590802653601

14. Berzofsky JA, Terabe M. The contrasting roles of NKT cells in tumor immunity. *Curr Mol Med* (2009) 9(6):667–72. doi:10.1089/cmm.2010.0052

15. Sada-Ovalle I, Chiba A, Gonzales A, Brenner MB, Behar SM. Invariant NKT cells recognize *Mycobacterium tuberculosis*-infected macrophages, produce interferon-gamma, and kill intracellular bacteria. *PLoS Pathog* (2008) 4(12):e1000239. doi:10.1371/journal.ppat.1000239

16. Chackerian A, Alt J, Perera V, Behar SM. Activation of NKT cells protects mice from tuberculosis. *J Infect Immun* (2002) 70(11):6302–9. doi:10.1128/JI.70.11.6302-6309.2002

17. He Y, Xiao R, Ji X, Li L, Chen L, Xiong J, et al. EBV promotes human CD8 NKT cell development. *PLoS Pathog* (2010) 6(5):e1000915. doi:10.1371/journal.ppat.1000915

18. Yuling H, Ruijing X, Li X, Jiang R, Zou Y, Yuan J, et al. EBV-infected human CD8+ NKT cells suppress tumorigenesis by EBV-associated malignancies. *Cancer Res* (2009) 69(20):7935–44. doi:10.1158/0008-5472.CAN-09-0828

19. Xiao W, Li L, Zhou R, Xiao R, Wang Y, Ji X, et al. EBV-infected human CD8(+) NKT cells synergise CD4(+) T cells suppressing EBV-associated tumours upon induction of Th1-bias. *Cell Mol Immunol* (2009) 6(5):367–79. doi:10.1038/cmi.2009.48

20. Eguchi T, Kumagai K, Kobayashi H, Shigematsu H, Kitaura K, Suzuki S, et al. Critical role of Valpha14+ natural killer T cells in the innate phase of host defense to nickel allergy. *Cell Immunol* (2013) 284(1–2):163–71. doi:10.1016/j.cellimm.2013.07.010

21. Tupin E, Nicoletti A, Elhage R, Rudling M, Ljunggren HG, Hansson GK, et al. CD1d-dependent activation of NKT cells aggravates atherosclerosis. *J Exp Med* (2004) 199(3):417–22. doi:10.1084/jem.20030997

22. Fernandez CS, Chan AC, Kyparissoudis K, De Rose R, Godfrey DI, Kent SJ. Critical role of Valpha14+ natural killer T cells in the innate phase of host protection against *Streptococcus pneumoniae* infection. *Eur J Immunol* (2003) 33(12):3322–30. doi:10.1002/eji.200324254

23. Stanic AK, De Silva AD, Park JJ, Sriram V, Ichikawa S, Hirabayashi Y, et al. Defective presentation of the CD1d1-restricted natural Va14Ja18 NKT lymphocyte antigen caused by beta-D-glucosylceramide synthase deficiency. *Proc Natl Acad Sci U S A* (2003) 100(4):1849–54. doi:10.1073/pnas.0430327100
60. Wu YL, Ding YP, Tanaka Y, Shen LW, Wei CH, Minato N, et al. Gammadelta T cells in human anti-infection immunity. Cell Mol Immunol (2013) 10(1):50–7. doi:10.1038/cmi.2012.43

61. Kroca M, Johannson A, Sjostedt A, Tarnvik A. V gamma 9 delta 2 T cells in human legionellosis. Clin Diagn Lab Immunol (2001) 8(5):949–54. doi:10.1128/CDLI.8.5.949-954.2001

62. Zheng J, Liu Y, Lau YL, Tu W. Gammadelta-T cells: an unpolished sword in human anti-infection immunity. Cell Mol Immunol (2013) 10(1):50–7. doi:10.1038/cmi.2012.43

63. Peichold K, Wesch D, Schondelmaier S, Kabeltitz D. Primary activation of V gamma 9 expressing gamma delta T cells by Mycobacterium tuberculosis. Requirement for Th1-type CD4 T cell help and inhibition by IL-10. J Immunol (1994) 152(10):4984–92.

64. Behr C, Pouport P, Peyrat MA, Poquet Y, Constant P, Dubois P, et al. Plasmodium falciparum stimuli for human gammadelta T cells are related to phosphorylated antigens of mycobacteria. Infect Immun (1996) 64(8):2892–6.

65. Arigoni D, Sagner S, Latzel C, Eisenreich W, Bacher A, Zenk MH. Terpenoid biosynthesis from 1-deoxy-D-xylulose in higher plants by intracellular skeletal rearrangement. Nat Protoc (2010) 5(20):10600–5. doi:10.1038/nprot.2010.10600

66. Espиноsa E, Belmanto C, Pont F, Luciani B, Pouport R, Romagné F, et al. Chemical synthesis and biological activity of bromohydryd pyrophosphate, a potent stimulator of human gamma delta T cells. J Biol Chem (2001) 276(21):18337–44. doi:10.1074/jbc.M100495200

67. Harly C, Guillaume Y, Nedelc S, Peigné CM, Mönkkönen H, Mönkkönen J, et al. Key implication of CD277/butfurin-3 (BTNA3) in cellular stress sensing by a major human gammadelta T-cell subset. Blood (2012) 120(11):2269–79. doi:10.1182/blood-2012-05-430470

68. Luoma AM, Castro CD, Mayassi T, Bembrin LA, Bai L, Picard D, et al. Crystal structure of Vdelta1 T cell receptor in complex with CD1d-sulfated shows NF-kB-like recognition of a self lipid by human gammadelta T cells. Immunity (2013) 39(6):1032–42. doi:10.1016/j.immuni.2013.11.001

69. Silva A, Mount A, Krstevska K, Pejoski D, Hardy MR, Owczarek C, et al. The combination of ISCOMATRIX adjuvant and TLN agonists induces regulation of established solid tumors in vivo. J Immunol (2015) 194(5):2199–207. doi:10.4049/jimmunol.1402228

70. Sandstrom A, Peigné CM, Léger A, Crooks JE, Konczak F, Gesnel MC, et al. The intracellular B30.2 domain of butyrophilin 3A1 binds phosphoantigens to mediate activation of human Vgamma9Vdelta2 T cells. Immunity (2014) 40(4):490–500. doi:10.1016/j.immuni.2014.03.003

71. Vavassori S, Kumar A, Wan GS, Ramanjaneyulu GS, Cavallari M, Ed Daker S, et al. Butyrophilin 3A1 binds phosphorylated antigens and stimulates human gammadelta T cells. Nat Immunol (2013) 14(9):908–16. doi:10.1038/ni.2665

72. Miyagawa F, Tanaka Y, Yamashita S, Minato N. Essential requirement of antigen presentation by monocyte lineage cells for the activation of primary human gamma delta T cells by aminobisphosphonate antigen. J Immunol (2001) 166(9):5508–14. doi:10.4049/jimmunol.166.9.5508

73. Brandes M, Willimmann K, Moser B. Professional antigen-presentation function by human gammadelta T cells. Science (2005) 309(5732):264–8. doi:10.1126/science.110287

74. Shin S, El-Diwany R, Schaffert S, Adams El, Garcia KC, Pereira P, et al. Antigen recognition determinants of gammadelta T cell receptors. Science (2005) 308(5719):252–5. doi:10.1126/science.1106480

75. Sarkonida G, Wang H, Puan KJ, Liu XH, Lee HK, Song Y, et al. Photoaffinity antigens for human gammadelta T cells. J Immunol (2008) 181(11):7738–50. doi:10.4049/jimmunol.181.11.7738

76. Collins C, Wolfe J, Roessner K, Shi C, Sigal LH, Budd RC. Lyme arthritis synovial gammadelta T cells instruct dendritic cells via fas ligand. J Immunol (2005) 175(9):5656–65. doi:10.4049/jimmunol.175.9.5656

77. Leslie DS, Vincent MS, Spada FM, Das H, Sugita M, Morita CT, et al. CD1-mediated gammadelta T-cell maturation and dendritic cell education. J Exp Med (2002) 196(12):1575–84. doi:10.1084/jem.20021515

78. DiTirro J, Rhoades ER, Roberts AD, Burke JM, Mukasa A, Cooper AM, et al. Disruption of the cellular inflammatory response to Listeria monocytogenes infection in mice with disruptions in targeted genes. Infect Immun (1998) 66(5):2284–9.

79. Sween MJ, Freeman MM, Ziegler HK. Changes in peritoneal myeloid populations and their proinflammatory cytokine expression during infection with Listeria monocytogenes are altered in the absence of gamma/delta T cells. J Leukoc Biol (2004) 76(1):104–15. doi:10.1189/jlb.1103574
80. Tilloy F, Treiner E, Park SH, Garcia C, Lemonnier F, de la Salle H, et al. An invariant T cell receptor alpha chain defines a novel TAP-independent major histocompatibility complex class Ib-restricted alpha/beta T cell subpopulation in mammals. *J Exp Med* (1999) **189**(12):1907–21.

81. Seach N, Guerri L, Le Bourhis L, Mburu Y, Cui Y, Bessoles S, et al. Double-negative thymocytes select mucosal-associated invariant T cells. *J Immunol* (2013) **191**(12):6002–9. doi:10.4049/jimmunol.1301212.

82. Billerbeck E, Kang YH, Walker L, Lockstone H, Grafmueller S, Fleming V, et al. Analysis of CD161 expression on human CD8+ T cells defines a distinct functional subset with tissue-homing properties. *Proc Natl Acad Sci U S A* (2010) **107**(7):3006–11. doi:10.1073/pnas.0914839107.

83. Takahashi T, Dejbakhsh-Jones S, Strober S. Expression of CD161 (NKR-P1A) defines subsets of human CD4 and CD8 T cells with different functional activities. *J Immunol* (2006) **176**(1):211–6. doi:10.4049/jimmunol.176.1.211.

84. Maggi L, Santarlasci V, Capone M, Peired A, Frosali F, Crome SQ, et al. CD161 is a marker of all human IL-17-producing T-cell subsets and is induced by RORC. *Eur J Immunol* (2010) **40**(8):2174–81. doi:10.1002/eji.200904257.

85. Turtle CJ, Swanson HM, Fuji H, Estey EH, Riddell SR. A distinct subset of self-renewing human memory CD8+ T cells survives cytotoxic chemotherapy. *Immunity* (2009) **31**(5):834–44. doi:10.1016/j.immuni.2009.09.015.

86. Dusseaux M, Martin E, Serriari N, Péguillet I, Premel V, Louis D, et al. Human MAIT cells are xenobiotic-resistant, tissue-targeted, CD161hi IL-17-secreting T cells. *Blood* (2011) **117**(4):1250–9. doi:10.1182/blood-2010-08-303339.

87. Kjer-Nielsen L, Patel O, Corbett AJ, Le Nours J, Meehan B, Liu L, et al. MAIT presents microbial vitamin B metabolites to MAIT cells. *Nature* (2012) **491**(7426):717–23. doi:10.1038/nature11605.

88. Gold MC, Eid T, Smyk-Pearson S, Eberling Y, Swarbrick GM, Langley SM, et al. Human thymic MR1-restricted MAIT cells are innate pathogen-reactive effectors that adapt following thymic egress. *Mucosal Immunol* (2013) **6**(1):35–44. doi:10.1038/mi.2012.45.

89. Le Bourhis L, Martin E, Pégüillet I, Guihot A, Froux N, Coré M, et al. Antimicrobial activity of mucosal-associated invariant T cells. *Nat Immunol* (2010) **11**(8):701–8. doi:10.1038/ni.1890.

90. Gold MC, Cerris S, Smyk-Pearson S, Cansler ME, Vogt TM, Delepine J, et al. Human mucosal associated invariant T cells detect bacterially infected cells. *PLoS Biol* (2010) **8**(6):e1000407. doi:10.1371/journal.pbio.1000407.

91. Georgel P, Radosavljevic M, Macquin C, Bahram S. The non-conventional MHC class I MR1 molecule controls infection by *Klebsiella pneumoniae* in mice. *Mol Immunol* (2011) **48**(5):769–75. doi:10.1016/j.molimm.2010.12.002.

92. Chua WJ, Truscott SM, Eickhoff CS, Blazevic A, Hoft DF, Hansen TH. Polyclonal mucosa-associated invariant T cells have unique innate functions in bacterial infection. * Infect Immun* (2012) **80**(9):3256–67. doi:10.1128/IAI.00279-12.

93. Meierovich A, Yankelevich WJ, Cowley SC. MAIT cells are critical for optimal mucosal immune responses during in vivo pulmonary bacterial infection. *Proc Natl Acad Sci U S A* (2013) **110**(33):E3119–28. doi:10.1073/pnas.1302799110.

94. Uscher JE, Klenerman P, Willberg CB. Mucosal-associated invariant T-cells: new players in anti-bacterial immunity. *Front Immunol* (2014) 5:450. doi:10.3389/fimmu.2014.00450.

95. Wong EB, Aklimlili NA, Govender P, Sullivan ZA, Cosgrove C, Pillay M, et al. Low levels of peripheral CD161+CD8+ mucosal associated invariant T (MAIT) cells are found in HIV and HIV/TB co-infection. *PLoS One* (2013) **8**(12):e83474. doi:10.1371/journal.pone.0083474.

96. Grimaldi D, Le Bourhis L, Sauneuf B, Dechartres A, Rousseau C, Ouaz F, et al. Specific MAIT cell behaviour among innate-like T lymphocytes in critically ill patients with severe infections. *Intensive Care Med* (2014) **40**(2):192–201. doi:10.1007/s00134-013-3163-x.

97. Reantragoon R, Kjer-Nielsen L, Patel O, Chen Z, Ilbing PT, Bhatti M, et al. Antigen-loaded MR1 tetramers define T cell receptor heterogeneity in mucosal-associated invariant T cells. *J Exp Med* (2013) **210**(11):2305–20. doi:10.1084/jem.20130958.

98. Reantragoon R, Kjer-Nielsen L, Patel O, Chen Z, Ilbing PT, Bhatti M, et al. Structural insight into MR1-mediated recognition of the mucosal associated invariant T cell receptor. *J Exp Med* (2012) **209**(4):761–74. doi:10.1084/jem.20112095.

99. Nauciel C, Espinasse-Maes F. Role of gamma interferon and tumor necrosis factor alpha in resistance to *Salmonella* typhimurium infection. *Infect Immun* (1992) **60**(2):450–4.

100. Lo WE, Ong H, Metcalf ES, Soloski MJ. T cell responses to Gram-negative intracellular bacterial pathogens: a role for CD8+ T cells in immunity to *Salmonella* infection and the involvement of MHC class Ib molecules. *J Immunol* (1999) **162**(9):5398–406.

101. Buchmeier NA, Heffron F. Inhibition of macrophage phagosome-lysosome fusion by *Salmonella* typhimurium. *Infect Immun* (1991) **59**(7):2232–8.

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2015 Gao and Williams. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.